ImmunityBio, Inc. (IBRX)
USD 2.65
(-6.36%)
USD 2.65
(-6.36%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 622 Thousand | 240 Thousand | 934 Thousand | 605 Thousand | 2.2 Million | 47 Thousand |
| Cost of Revenue | 18.51 Million | 24.19 Million | - | 9.14 Million | 9.01 Million | -3.11 Million |
| Gross Profit | -17.89 Million | -23.95 Million | 934 Thousand | -8.54 Million | -6.81 Million | 3.15 Million |
| Operating Expenses | 362.87 Million | 350.85 Million | 331.21 Million | 210.82 Million | 158.45 Million | 88.88 Million |
| Selling, General and Administrative Expenses | 129.62 Million | 102.7 Million | 135.25 Million | 71.31 Million | 46.45 Million | 35.46 Million |
| Research and Development Expenses | 232.36 Million | 248.14 Million | 195.95 Million | 139.5 Million | 111.99 Million | 53.41 Million |
| Other Expenses | 886 Thousand | -736 Thousand | 193 Thousand | 1.48 Million | -534 Thousand | - |
| Cost and Expenses | 362.87 Million | 350.85 Million | 331.21 Million | 210.82 Million | 158.45 Million | 98.43 Million |
| Operating Income | -362.25 Million | -351.29 Million | -330.28 Million | -220.88 Million | -156.25 Million | -98.38 Million |
| Interest Expense | 129.19 Million | 63.51 Million | 14.84 Million | 9.07 Million | 5.92 Million | 433 Thousand |
| Income Tax Expense | -40 Thousand | 34 Thousand | 9000.00 | -1.84 Million | -105 Thousand | -503 Thousand |
| Earnings before Tax | -583.89 Million | -417.28 Million | -349.83 Million | -226.03 Million | -160.26 Million | -96.72 Million |
| Net Income | -583.19 Million | -417.32 Million | -349.84 Million | -224.18 Million | -160.15 Million | -96.22 Million |
| Earnings Per Share Basic | -1.15 | -1.04 | -0.90 | -0.59 | -0.42 | -1.22 |
| Earnings Per Share Diluted | -1.15 | -1.04 | -0.90 | -0.59 | -0.42 | -1.22 |
| Weighted Average Shares Outstanding | 508.63 Million | 399.9 Million | 389.23 Million | 383.17 Million | 383.17 Million | 79.13 Million |
| Weighted Average Shares Outstanding (Diluted) | 508.63 Million | 399.9 Million | 389.23 Million | 383.17 Million | 383.17 Million | 79.13 Million |
| Gross Margin | -28.76 | -99.80 | 1.00 | -14.12 | -3.09 | 67.17 |
| EBIT Margin | -701.26 | -1433.24 | -338.66 | -322.53 | -63.57 | -1890.09 |
| Profit Margin | -937.61 | -1738.83 | -374.57 | -370.56 | -72.73 | -2047.36 |
| EBITDA | -436.18 Million | -335.51 Million | -315.38 Million | -187.93 Million | -142.27 Million | -86.74 Million |
| Earnings Before Tax Margin | -582.40 | -1463.74 | -353.62 | -365.09 | -70.96 | -2093.38 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 1.04 Million | 40 Thousand | 139 Thousand | 622 Thousand | 82 Thousand | 41 Thousand |
| Cost of Revenue | 4.4 Million | 4.55 Million | 4.56 Million | 18.51 Million | 4.58 Million | 6.31 Million |
| Gross Profit | -3.35 Million | -4.51 Million | -4.42 Million | -17.89 Million | -4.5 Million | -6.27 Million |
| Operating Expenses | 100.38 Million | 90.68 Million | 80.07 Million | 343.47 Million | 80.21 Million | 85.18 Million |
| Selling, General and Administrative Expenses | 49.25 Million | 37.83 Million | 29.04 Million | - | 31.81 Million | 32.01 Million |
| Research and Development Expenses | 51.12 Million | 52.85 Million | 51.03 Million | - | 48.4 Million | 53.16 Million |
| Other Expenses | -17 Thousand | -20 Thousand | -37.02 Million | -38.42 Million | 6.47 Million | -6.79 Million |
| Cost and Expenses | 100.38 Million | 95.23 Million | 84.64 Million | 361.98 Million | 80.21 Million | 85.18 Million |
| Operating Income | -99.33 Million | -95.19 Million | -84.5 Million | -361.36 Million | -80.13 Million | -85.14 Million |
| Interest Expense | -29.79 Million | 37.48 Million | 32.12 Million | 129.19 Million | -35.02 Million | 32.23 Million |
| Income Tax Expense | -4.4 Million | -21 Thousand | -40 Thousand | -40 Thousand | -4.58 Million | 20.88 Million |
| Earnings before Tax | -134.56 Million | -134.13 Million | -233.45 Million | -583.89 Million | -95.58 Million | -138.21 Million |
| Net Income | -134.56 Million | -134.1 Million | -233.39 Million | -583.19 Million | -95.58 Million | -137.87 Million |
| Earnings Per Share Basic | -0.20 | -0.20 | -0.35 | - | -0.19 | -0.32 |
| Earnings Per Share Diluted | -0.20 | -0.20 | -0.35 | - | -0.19 | -0.32 |
| Weighted Average Shares Outstanding | 686.93 Million | 672.83 Million | 670.86 Million | 508.63 Million | 498.37 Million | 437.45 Million |
| Weighted Average Shares Outstanding (Diluted) | 686.93 Million | 672.83 Million | 670.86 Million | 508.63 Million | 498.37 Million | 437.45 Million |
| Gross Margin | -3.21 | -112.88 | -31.83 | -28.76 | -54.91 | -153.10 |
| EBIT Margin | -94.87 | -2266.02 | -575.10 | - | -977.27 | -2216.68 |
| Profit Margin | -128.52 | -3352.72 | -1679.08 | -937.61 | -1165.63 | -3362.90 |
| EBITDA | -99.33 Million | -90.64 Million | -79.93 Million | - | -80.13 Million | -90.88 Million |
| Earnings Before Tax Margin | -94.87 | -2379.90 | -607.94 | -580.97 | -977.27 | -2076.71 |
NVEC
7616
JMBRF
4845
MGRM
300554